Delineation of the phenotypes and genotypes of PIK3CA-related overgrowth spectrum in East asians.


Journal

Molecular genetics and genomics : MGG
ISSN: 1617-4623
Titre abrégé: Mol Genet Genomics
Pays: Germany
ID NLM: 101093320

Informations de publication

Date de publication:
09 Jul 2024
Historique:
received: 26 01 2024
accepted: 20 06 2024
medline: 9 7 2024
pubmed: 9 7 2024
entrez: 9 7 2024
Statut: epublish

Résumé

PIK3CA-related overgrowth spectrum (PROS) is an umbrella term to describe a diverse range of developmental disorders. Research to date has predominantly emerged from Europe and North America, resulting in a notable scarcity of studies focusing on East Asian populations. Currently, the prevalence and distribution of PIK3CA variants across various genetic loci and their correlation with distinct phenotypes in East Asian populations remain unclear. This study aims to elucidate the phenotype-genotype correlations of PROS in East Asian populations. We presented the phenotypes and genotypes of 82 Chinese patients. Among our cohort, 67 individuals carried PIK3CA variants, including missense, frameshift, and splice variants. Six patients presented with both PIK3CA and an additional variant. Seven PIK3CA-negative patients exhibited overlapping PROS manifestations with variants in GNAQ, AKT1, PTEN, MAP3K3, GNA11, or KRAS. An integrative review of the literature pertaining to East Asian populations revealed that specific variants are uniquely associated with certain PROS phenotypes. Some rare variants were exclusively identified in cases of megalencephaly and diffuse capillary malformation with overgrowth. Non-hotspot variants with undefined oncogenicity were more common in CNS phenotypes. Diseases with vascular malformation were more likely to have variants in the helical domain, whereas phenotypes involving adipose/muscle overgrowth without vascular abnormalities predominantly presented variants in the C2 domain. Our findings underscore the unique phenotype-genotype patterns within the East Asian PROS population, highlighting the necessity for an expanded cohort to further elucidate these correlations. Such endeavors would significantly facilitate the development of PI3Kα selective inhibitors tailored for the East Asian population in the future.

Identifiants

pubmed: 38980418
doi: 10.1007/s00438-024-02159-w
pii: 10.1007/s00438-024-02159-w
doi:

Substances chimiques

Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

66

Subventions

Organisme : Major and Key Cultivation Projects of Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine
ID : JYZP005
Organisme : Treatment and mechanism of PI3K/mTOR dual-target inhibitor (WX390) on PIK3CA-related overgrowth spectrum (PROS)
ID : JYWO22075
Organisme : Shanghai Sailing Program
ID : 22YF1421900
Organisme : Rare Disease Registration Platform of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
ID : JYHJB02

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Belli C, Repetto M, Anand S, Porta C, Subbiah V, Curigliano G (2023) The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br J Cancer 128(12):2150–2162
pubmed: 36914722 pmcid: 10241926 doi: 10.1038/s41416-023-02221-1
Briand C, Galmiche-Rolland L, Vabres P, Couloigner V, Audebert S, Misery L et al (2020) Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation. Pediatr Dermatol 37(6):1128–1130
pubmed: 32770747 doi: 10.1111/pde.14302
Brouillard P, Schlogel MJ, Homayun Sepehr N, Helaers R, Queisser A, Fastre E et al (2021) Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations. Orphanet J Rare Dis 16(1):267
pubmed: 34112235 pmcid: 8194016 doi: 10.1186/s13023-021-01898-y
Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM (2021) A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis 16(1):306
pubmed: 34238334 pmcid: 8268514 doi: 10.1186/s13023-021-01929-8
Canaud G, Lopez Gutierrez JC, Irvine AD, Vabres P, Hansford JR, Ankrah N et al (2023) Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med 25(12):100969
pubmed: 37634128 doi: 10.1016/j.gim.2023.100969
Chen W, Tian X, Chen L, Huang W (2021) Macrodactyly of the foot resulting from plantar nerve impairment. J Plast Reconstr Aesthet Surg 74(8):1840–1847
pubmed: 33384233 doi: 10.1016/j.bjps.2020.11.032
Chen H, Sun B, Gao W, Qiu Y, Hua C, Lin X (2023) Delineation of the phenotypes and genotypes of facial infiltrating lipomatosis associated with PIK3CA mutations. Orphanet J Rare Dis 18(1):189
pubmed: 37452404 pmcid: 10347770 doi: 10.1186/s13023-023-02786-3
Cottrell CE, Bender NR, Zimmermann MT, Heusel JW, Corliss M, Evenson MJ et al (2021) Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth. Genet Med 23(10):1882–1888
pubmed: 34040190 pmcid: 8486672 doi: 10.1038/s41436-021-01211-z
Couto JA, Konczyk DJ, Vivero MP, Kozakewich HPW, Upton J, Fu X et al (2017) Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis. Pediatr Res 82(5):850–854
pubmed: 28665924 pmcid: 5645230 doi: 10.1038/pr.2017.155
Diociaiuti A, Rotunno R, Pisaneschi E, Cesario C, Carnevale C, Condorelli AG et al (2022) Clinical and molecular spectrum of sporadic vascular malformations: a single-center study. Biomedicines, 10(6)
Dogruluk T, Tsang YH, Espitia M, Chen F, Chen T, Chong Z et al (2015) Identification of variant-specific functions of PIK3CA by Rapid phenotyping of rare mutations. Cancer Res 75(24):5341–5354
pubmed: 26627007 pmcid: 4681596 doi: 10.1158/0008-5472.CAN-15-1654
Ermira Pazolli RK (2021) RLY-2608: the first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models San Antonio Breast Cancer Symposium, December 7–10
Garneau AP, Haydock L, Tremblay LE, Isenring P (2021) Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America. J Mol Med (Berl) 99(3):311–313
pubmed: 33392635 doi: 10.1007/s00109-020-02030-6
Garreta Fontelles G, Pardo Pastor J, Grande C, Moreillo (2022) Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum. Br J Clin Pharmacol
Goncalves MD, Hopkins BD, Cantley LC (2018) Phosphatidylinositol 3-Kinase, Growth disorders, and Cancer. N Engl J Med 379(21):2052–2062
pubmed: 30462943 doi: 10.1056/NEJMra1704560
Goss JA, Konczyk DJ, Smits P, Sudduth CL, Bischoff J, Liang MG et al (2020) Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants. Clin Genet 97(5):736–740
pubmed: 31909475 pmcid: 8128061 doi: 10.1111/cge.13702
Hanafusa H, Morisada N, Nomura T, Kobayashi D, Akasaka Y, Ye MJ et al (2019) A girl with CLOVES syndrome with a recurrent PIK3CA somatic mutation and pancreatic steatosis. Hum Genome Var 6:31
pubmed: 31263565 pmcid: 6591404 doi: 10.1038/s41439-019-0063-9
Holowatyj AN, Wen W, Gibbs T, Seagle HM, Keller SR, Edwards DRV et al (2023) Racial/Ethnic and sex differences in somatic Cancer gene mutations among patients with early-onset Colorectal Cancer. Cancer Discov 13(3):570–579
pubmed: 36520636 pmcid: 10436779 doi: 10.1158/2159-8290.CD-22-0764
Hori Y, Hirose K, Ozeki M, Hata K, Motooka D, Tahara S et al (2022) PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in fibfibroipose vascular anomaly (FAVA). Diagn Pathol 17(1):19
pubmed: 35094709 pmcid: 8802443 doi: 10.1186/s13000-022-01199-3
Hu P, Mondino A, Skolnik EY, Schlessinger J (1993) Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol Cell Biol 13(12):7677–7688
pubmed: 8246984 pmcid: 364839
Itoh K, Pooh R, Shimokawa O, Fushiki S (2023) Somatic mosaicism of the PI3K-AKT-MTOR pathway is associated with hemimegalencephaly in fetal brains. Neuropathology 43(2):190–196
pubmed: 36325654 doi: 10.1111/neup.12875
Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC et al (2015) PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 167A(2):287–295
pubmed: 25557259 doi: 10.1002/ajmg.a.36836
Keppler-Noreuil KM, Parker VE, Darling TN, Martinez-Agosto JA (2016) Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet 172(4):402–421
pubmed: 27860216 pmcid: 5592089 doi: 10.1002/ajmg.c.31531
Kim YM, Lee Y, Choi Y, Choi IH, Heo SH, Choi JM et al (2022) Clinical and genetic analyses of patients with lateralized overgrowth. BMC Med Genomics 15(1):206
pubmed: 36175890 pmcid: 9524090 doi: 10.1186/s12920-022-01362-1
Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T et al (2017) Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med 19(9):989–997
pubmed: 28151489 doi: 10.1038/gim.2016.220
Li JF, Tian GL, Pan H, Zhang WT, Li DC, Liu JD et al (2022) An analysis of the pathogenic genes and Mutation sites of Macrodactyly. Pharmgenomics Pers Med 15:55–64
pubmed: 35125881 pmcid: 8809672
Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV et al (2015) Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 166(4):1048–1054e1041
pubmed: 25681199 pmcid: 4498659 doi: 10.1016/j.jpeds.2014.12.069
Maclellan RA, Luks VL, Vivero MP, Mulliken JB, Zurakowski D, Padwa BL et al (2014) PIK3CA activating mutations in facial infiltrating lipomatosis. Plast Reconstr Surg 133(1):12e–19e
pubmed: 24374682 doi: 10.1097/01.prs.0000436822.26709.7c
Madsen RR, Vanhaesebroeck B, Semple RK (2018) Cancer-Associated PIK3CA mutations in Overgrowth disorders. Trends Mol Med 24(10):856–870
pubmed: 30197175 pmcid: 6185869 doi: 10.1016/j.molmed.2018.08.003
Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B et al (2016) PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight, 1(9)
Morgos DT, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S et al (2024) Targeting PI3K/AKT/mTOR and MAPK signaling pathways in gastric Cancer. Int J Mol Sci, 25(3)
Morin G, Degrugillier-Chopinet C, Vincent M, Fraissenon A, Aubert H, Chapelle C et al (2022) Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. J Exp Med, 219(3)
Mussa A, Leoni C, Iacoviello M, Carli D, Ranieri C, Pantaleo A et al (2023) Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants. J Med Genet 60(2):163–173
pubmed: 35256403 doi: 10.1136/jmedgenet-2021-108093
Pagliazzi A, Oranges T, Traficante G, Trapani C, Facchini F, Martin A et al (2021) PIK3CA-Related overgrowth Spectrum from diagnosis to targeted therapy: a case of CLOVES syndrome treated with Alpelisib. Front Pediatr 9:732836
pubmed: 34568242 pmcid: 8459713 doi: 10.3389/fped.2021.732836
Park HJ, Shin CH, Yoo WJ, Cho TJ, Kim MJ, Seong MW et al (2020) Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations. Orphanet J Rare Dis 15(1):205
pubmed: 32778138 pmcid: 7418424 doi: 10.1186/s13023-020-01480-y
Reynolds G, Cardaropoli S, Carli D, Luca M, Gazzin A, Coppo P et al (2023) Epidemiology of the disorders of the Pik3ca-related overgrowth spectrum (pros). Eur J Hum Genet 31(11):1333–1336
pubmed: 37365400 doi: 10.1038/s41431-023-01414-9
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424
pubmed: 25741868 pmcid: 4544753 doi: 10.1038/gim.2015.30
Riviere JB, Mirzaa GM, O’Roak BJ, Beddaoui M, Alcantara D, Conway RL et al (2012) De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44(8):934–940
pubmed: 22729224 pmcid: 3408813 doi: 10.1038/ng.2331
Sasaki Y, Ishikawa K, Hatanaka KC, Oyamada Y, Sakuhara Y, Shimizu T et al (2023) Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population: list the full names and institutional addresses for all authors. Orphanet J Rare Dis 18(1):270
pubmed: 37667289 pmcid: 10478188 doi: 10.1186/s13023-023-02893-1
Sim NS, Ko A, Kim WK, Kim SH, Kim JS, Shim KW et al (2019) Precise detection of low-level somatic mutation in resected epilepsy brain tissue. Acta Neuropathol 138(6):901–912
pubmed: 31377847 doi: 10.1007/s00401-019-02052-6
Singh S, Bradford D, Li X, Mishra-Kalyani PS, Shen YL, Wang L et al (2023) FDA approval Summary: Alpelisib for PIK3CA-related overgrowth spectrum (PROS). Clin Cancer Res
Suzuki Y, Enokido Y, Yamada K, Inaba M, Kuwata K, Hanada N et al (2017) The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS). Oncotarget 8(28):45470–45483
pubmed: 28525374 pmcid: 5542201 doi: 10.18632/oncotarget.17566
Tian W, Huang Y, Sun L, Guo Y, Zhao S, Lin M et al (2020) Phenotypic and genetic spectrum of isolated macrodactyly: somatic mosaicism of PIK3CA and AKT1 oncogenic variants. Orphanet J Rare Dis 15(1):288
pubmed: 33054853 pmcid: 7556951 doi: 10.1186/s13023-020-01572-9
Tian W, Sun L, Zhang Q, Zhao J, Guo Y, Zhong W et al (2022) Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities. Mol Genet Genomics 297(2):387–396
pubmed: 35122151 doi: 10.1007/s00438-022-01853-x
Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP et al (2018) Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 558(7711):540–546
pubmed: 29899452 pmcid: 7610773 doi: 10.1038/s41586-018-0217-9
Wu J, Tian W, Tian G, Sumner K, Hutchinson DT, Ji Y (2018) An investigation of PIK3CA mutations in isolated macrodactyly. J Hand Surg Eur Vol 43(7):756–760
pubmed: 29661094 doi: 10.1177/1753193418770366
Wu J, Tian G, Ji Y, Higgins JP, Lee WPA (2020) Clinical characteristics of 90 Macrodactyly cases. J Hand Surg Am, 45(10): p. 982 e981-982 e985.
Xu J, Liu M, Yuan H, Liu Z, Zhu D (2022) Case Report: primary pleural angiosarcoma in a patient with klippel-trenaunay syndrome. Front Genet 13:792466
pubmed: 35154272 pmcid: 8831743 doi: 10.3389/fgene.2022.792466
Xue S, Liu Q, Zhao Y, Kong L, Fu F, Gong Y et al (2023) Fibroadipose vascular anomaly: a clinicopathological study of 75 cases. Histopathology 83(2):286–297
pubmed: 37099413 doi: 10.1111/his.14923
Yan W, Zhang B, Wang H, Mo R, Jiang X, Qin W et al (2021) Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway. Hereditas 158(1):18
pubmed: 34074347 pmcid: 8170820 doi: 10.1186/s41065-021-00184-y
Yeung KS, Tso WWY, Ip JJK, Mak CCY, Leung GKC, Tsang MHY et al (2017a) Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism. Mol Autism 8:66
pubmed: 29296277 pmcid: 5738835 doi: 10.1186/s13229-017-0182-4
Yeung KS, Ip JJ, Chow CP, Kuong EY, Tam PK, Chan GC et al (2017b) Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum. Am J Med Genet A 173(4):978–984
pubmed: 28328134 doi: 10.1002/ajmg.a.38105
Yoh Y, Shiohama T, Uchida T, Ebata R, Kobayashi H, Okunushi K et al (2023) Case report: progressive pulmonary artery hypertension in a case of megalencephaly-capillary malformation syndrome. Front Genet 14:1221745
pubmed: 37614820 pmcid: 10442816 doi: 10.3389/fgene.2023.1221745
Zhang B, He R, Xu Z, Sun Y, Wei L, Li L et al (2023) Somatic mutation spectrum of a Chinese cohort of pediatrics with vascular malformations. Orphanet J Rare Dis 18(1):261
pubmed: 37658401 pmcid: 10474751 doi: 10.1186/s13023-023-02860-w

Auteurs

Hongrui Chen (H)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China.

Bin Sun (B)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China.

Hongyuan Liu (H)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China.

Wei Gao (W)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China.

Yajing Qiu (Y)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China.

Chen Hua (C)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China. worson78@163.com.

Xiaoxi Lin (X)

Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, P.R. China. xiaoxilin@shsmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH